Trial · NCT07880522
Subacromial Corticosteroid Injection Combined With Exercise in Supraspinatus Tendinopathy
NCT07880522, Not applicable, Active not recruiting, Dr.Rumeysa Türkoğlu
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Subacromial Corticosteroid Injection Combined With Exercise in Supraspinatus Tendinopathy. Trials, record NCT07880522. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07880522
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Subacromial Corticosteroid Injection Combined With Exercise in Supraspinatus Tendinopathy
- NCT number
- NCT07880522
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 56 participants, estimated
- Lead sponsor
- Dr.Rumeysa Türkoğlu
- Conditions
- Supraspinatus Tendinopathy
- Interventions
- Subacromial Triamcinolone Acetonide Injection, Intramuscular Saline Placebo Injection, Home-Based Exercise Program
- First posted
- 2026-10-19
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Supraspinatus Tendon Elasticity Measured by Shear Wave Elastography | Baseline and Week 12 | Supraspinatus tendon elasticity will be assessed using shear wave elastography (SWE). Measurements will be obtained from the tendon footprint and mid-substance regions, with at least three measurements taken from each region and the median value recorded. The change in tendon elasticity from baseline to week 12 will be evaluated. |
| Secondary | Change in Shoulder Pain Measured by Visual Analog Scale (VAS) | Baseline, Week 6, and Week 12 | Shoulder pain will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Rest pain, activity-related pain, and night pain will be recorded separately. Higher scores indicate greater pain severity. |
| Secondary | Change in Shoulder Function Measured by Constant-Murley Score | Baseline, Week 6, and Week 12 | Shoulder function will be assessed using the Constant-Murley Score, ranging from 0 to 100 points. The score evaluates pain, activities of daily living, range of motion, and strength. Higher scores indicate better shoulder function |
| Secondary | Change in Upper Extremity Disability Measured by QuickDASH | Baseline, Week 6, and Week 12 | Upper extremity disability will be assessed using the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire, scored from 0 to 100. Higher scores indicate greater disability and poorer upper extremity function. |
| Secondary | Change in Shoulder Pain and Disability Measured by SPADI | Baseline, Week 6, and Week 12 | Shoulder pain and disability will be assessed using the Shoulder Pain and Disability Index (SPADI), scored from 0 to 100. The scale includes pain and disability subscales. Higher scores indicate greater pain and disability. |
| Secondary | Change in Health-Related Quality of Life Measured by SF-12 | Baseline, Week 6, and Week 12 | Health-related quality of life will be assessed using the 12-Item Short Form Health Survey (SF-12). The SF-12 provides a Physical Component Summary (PCS-12) score and a Mental Component Summary (MCS-12) score, each ranging from 0 to 100. Higher scores indicate better health status and health-related quality of life. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07880522
GET https://conductscience.org/api/trials/v1/NCT07880522/registered